# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 02, 2023

### APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-37746 (Commission File Number) 81-1567056 (IRS Employer Identification No.)

2401 4th Avenue
Suite 1050
Seattle, Washington
(Address of Principal Executive Offices)

98121 (Zip Code)

Registrant's Telephone Number, Including Area Code: (206) 838-0500

#### Not Applicable (Former Name or Former Address, if Changed Since Last Report)

			<u></u>	
	eck the appropriate box below if the Form 8-K filing is owing provisions:	intended to simultaneously sa	atisfy the filing obligation of the registrant under any of the	
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)			
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)			
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))			
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			
	Securities	registered pursuant to Sect	ion 12(b) of the Act:	
		Trading		
	Title of each class	Symbol(s)	Name of each exchange on which registered	
	Common Stock, \$0.001 par value	APVO	The Nasdaq Stock Market LLC	
	icate by check mark whether the registrant is an emergi pter) or Rule 12b-2 of the Securities Exchange Act of 1		ed in Rule 405 of the Securities Act of 1933 (§ 230.405 of this oter).	
Em	erging growth company $\square$			
	n emerging growth company, indicate by check mark if revised financial accounting standards provided pursuan	9	t to use the extended transition period for complying with any new hange Act. $\square$	

#### Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 2, 2023, Aptevo Therapeutics Inc. (the "Company") held its 2023 Annual Meeting of Stockholders (the "Annual Meeting"), at which a quorum was present. Stockholders considered three proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 18, 2023 (the "Proxy Statement"). The final voting results with respect to each of the proposals acted upon at the 2023 Annual Meeting are set forth below.

#### **Proposal 1: Election of Directors**

The following two nominees, each of whom were named in the Proxy Statement, were elected to serve on the Board of Directors to hold office until the 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, based on the following votes:

	FOR	WITHHELD	BROKER NON-VOTES
Zsolt Harsanyi, Ph.D.	967,133	343,098	2,566,806
Barbara Lopez Kunz	716,175	594,056	2,566,806

#### Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm for 2023

The appointment of Moss Adams LLP to serve as the Company's independent registered public accounting firm for the year ending December 31, 2023 was approved based on the following votes:

FOR	AGAINST	ABSTAIN	
3,581,428	276,500	19,109	

Proposal 3: Approval, on a non-binding advisory basis, the compensation of the Company's named executive officer compensation as disclosed in the Proxy Statement.

The non-binding advisory proposal was approved based on the following votes:

FOR	AGAINST	ABSTAIN	BROKER NON-VOTES
969,344	332,792	8,095	2,566,806

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

APTEVO THERAPEUTICS INC.

Date: June 2, 2023 By: /s/ Marvin L. White

Marvin L. White

President and Chief Executive Officer